Comparative Pharmacology
Head-to-head clinical analysis: DULERA versus HALDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DULERA versus HALDRONE.
DULERA vs HALDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
Glucocorticoid receptor agonist; suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene transcription.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
Oral: Initial dose 50-100 mg twice daily; maintenance 25-50 mg twice daily. Maximum 200 mg/day.
None Documented
None Documented
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
Terminal elimination half-life: 2.6-3.8 hours. Clinical context: Short half-life requires multiple daily dosing; no significant accumulation with regular dosing.
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Renal: 20-30% as unchanged drug; biliary/fecal: 70-80% as metabolites and unchanged drug.
Category C
Category C
Corticosteroid/Beta2-Agonist Combination
Corticosteroid